FDA ap­proves Re­by­ota, Fer­ring's poop-based drug to fight C. diff in­fec­tion

The FDA ap­proved Fer­ring Phar­ma­ceu­ti­cals’ Re­by­ota drug on Wednes­day, a poop-based drug im­plant that can pre­vent the re­cur­rence of Clostrid­ioides dif­fi­cile in­fec­tion.

While the use of fe­cal mi­cro­bio­ta trans­plan­ta­tion (FMT) — re­plen­ish­ing a pa­tient’s gut with bac­te­ria from healthy fe­ces — has al­ready been hap­pen­ing with­out an FDA-ap­proved prod­uct, Re­by­ota is the first live bio­ther­a­peu­tic drug ap­proved by the agency to fight the po­ten­tial­ly dead­ly in­fec­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER